Teleflex Under Investigation for Securities Fraud Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2026
0mins
Should l Buy TFX?
Source: PRnewswire
- Executive Departure Impact: On January 8, 2026, Teleflex announced the immediate departure of CEO Liam Kelly, which resulted in a stock price drop of $16.52, or 13.06%, closing at $110.01 per share, indicating strong market reaction to leadership changes.
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Teleflex and certain officers have engaged in securities fraud or other unlawful business practices, advising investors to contact them for information on joining the class action, highlighting potential governance concerns.
- Legal Background: Pomerantz LLP is recognized as a premier firm in corporate, securities, and antitrust class litigation, having fought for victims of securities fraud for over 85 years, suggesting that this case may have broader legal implications.
- Investor Warning: As the investigation unfolds, Teleflex investors face potential financial risks, particularly as concerns over corporate governance and compliance may influence future investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TFX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TFX
Wall Street analysts forecast TFX stock price to rise
7 Analyst Rating
1 Buy
5 Hold
1 Sell
Hold
Current: 111.800
Low
122.00
Averages
136.20
High
155.00
Current: 111.800
Low
122.00
Averages
136.20
High
155.00
About TFX
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teleflex to Host Q4 2025 Earnings Call on February 26, 2026
- Earnings Call Schedule: Teleflex plans to host a conference call on February 26, 2026, at 8:00 a.m. Eastern Time to discuss its Q4 2025 financial results and operational updates, aiming to provide transparent communication to investors.
- Participation Details: Investors can pre-register via a provided link to receive dial-in information, and the call will also be accessible through a live audio webcast on the company’s website, ensuring broad participation and information dissemination.
- Replay Availability: An audio replay of the call will be available starting at 11:00 a.m. Eastern Time on February 26, 2026, accessible through the company’s website or by dialing specified numbers, enhancing information accessibility for stakeholders.
- Company Vision: Teleflex is committed to becoming the most trusted partner in healthcare, offering a diverse portfolio of medical technology solutions across various fields including anesthesia, emergency medicine, and interventional cardiology, reflecting its mission to drive innovation in healthcare.
See More
Teleflex to Host Q4 2025 Financial Results Conference Call
- Conference Call Schedule: Teleflex plans to host a conference call on February 26, 2026, at 8:00 a.m. Eastern Time to discuss its fourth quarter 2025 financial results and provide an operational update, aiming to enhance investor understanding and confidence in the company's performance.
- Participation Details: Investors can pre-register via a provided link to receive dial-in information, and the call will also be accessible through a live audio webcast on the company's website, ensuring broad participation and transparency.
- Replay Information: An audio replay of the call will be available starting at 11:00 a.m. Eastern Time on February 26, 2026, allowing investors to access the information conveniently through the company website or designated phone numbers.
- Company Background: Teleflex, as a global provider of medical technologies, is committed to improving health and quality of life, with a diverse portfolio covering anesthesia, emergency medicine, interventional cardiology, and more, showcasing its leadership in the healthcare industry.
See More
Teleflex Under Investigation for Securities Fraud Claims
- Executive Departure Impact: On January 8, 2026, Teleflex announced the immediate departure of CEO Liam Kelly, which resulted in a stock price drop of $16.52, or 13.06%, closing at $110.01 per share, indicating strong market reaction to leadership changes.
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Teleflex and certain officers have engaged in securities fraud or other unlawful business practices, advising investors to contact them for information on joining the class action, highlighting potential governance concerns.
- Legal Background: Pomerantz LLP is recognized as a premier firm in corporate, securities, and antitrust class litigation, having fought for victims of securities fraud for over 85 years, suggesting that this case may have broader legal implications.
- Investor Warning: As the investigation unfolds, Teleflex investors face potential financial risks, particularly as concerns over corporate governance and compliance may influence future investment decisions.
See More
Tejara Capital Increases Stake in Teleflex by 69,700 Shares
- Share Acquisition: Tejara Capital Ltd disclosed an acquisition of 69,700 shares of Teleflex in a February 5 SEC filing, with an estimated transaction value of $8.45 million, indicating confidence in the company's future prospects.
- Asset Allocation Shift: This purchase increased Tejara's stake in Teleflex to 2.23%, reflecting a strategic positioning in the medical device sector, despite the stock's nearly 39% decline over the past year.
- Financial Performance: Teleflex's recent earnings report revealed a 19.4% year-over-year increase in GAAP revenue to $913 million, with adjusted EPS rising to $3.67, showcasing operational growth despite impairment challenges.
- Market Positioning: Teleflex focuses on single-use medical devices and boasts a robust global distribution network, offering a relatively stable risk profile compared to Tejara's other high-volatility investments in energy and biotech sectors.
See More
Eos Management Establishes New Position in Teleflex
- New Position: Eos Management disclosed a new stake in Teleflex with 30,831 shares valued at $3.76 million as of December 31, indicating a strategic investment in the medical device sector.
- Holding Proportion: This position represents 1.48% of Eos's 13F reportable assets, reflecting confidence in Teleflex's potential despite a 42.5% decline in stock price over the past year.
- Performance Outlook Adjustment: Teleflex recently narrowed its 2025 revenue growth outlook from 9.0%-10.0% to 9.1%-9.6%, highlighting operational uncertainties that may impact investor confidence.
- Strategic Focus: Teleflex is shrinking to concentrate on high-acuity hospital markets and plans to improve long-term growth and margins through divestitures, which may present future opportunities for investors.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Affirm Holdings Upgrade: Needham analyst Kyle Peterson upgraded Affirm Holdings Inc (NASDAQ:AFRM) from Hold to Buy with a $100 price target, which, given its closing price of $68.71 on Monday, could attract more investor interest.
- CoStar Group Upgrade: BTIG analyst Jake Fuller upgraded CoStar Group Inc (NASDAQ:CSGP) from Neutral to Buy with a price target of $80, based on its closing price of $65.81 on Monday, suggesting increased market confidence following this upgrade.
- Teleflex Upgrade: Needham analyst Mike Matson upgraded Teleflex Inc (NYSE:TFX) from Hold to Buy with a target price of $138, considering its closing price of $104.20 on Monday, indicating potential upward movement in stock price due to this upgrade.
- CoreWeave Upgrade: Deutsche Bank analyst Brad Zelnick upgraded CoreWeave Inc (NASDAQ:CRWV) from Hold to Buy and raised the price target from $100 to $140, based on its closing price of $98.31 on Monday, which may trigger positive investor reactions to this rating change.
See More
Teleflex to Host Q4 2025 Earnings Call on February 26, 2026
- Earnings Call Schedule: Teleflex plans to host a conference call on February 26, 2026, at 8:00 a.m. Eastern Time to discuss its Q4 2025 financial results and operational updates, aiming to provide transparent communication to investors.
- Participation Details: Investors can pre-register via a provided link to receive dial-in information, and the call will also be accessible through a live audio webcast on the company’s website, ensuring broad participation and information dissemination.
- Replay Availability: An audio replay of the call will be available starting at 11:00 a.m. Eastern Time on February 26, 2026, accessible through the company’s website or by dialing specified numbers, enhancing information accessibility for stakeholders.
- Company Vision: Teleflex is committed to becoming the most trusted partner in healthcare, offering a diverse portfolio of medical technology solutions across various fields including anesthesia, emergency medicine, and interventional cardiology, reflecting its mission to drive innovation in healthcare.
See More
Teleflex to Host Q4 2025 Financial Results Conference Call
- Conference Call Schedule: Teleflex plans to host a conference call on February 26, 2026, at 8:00 a.m. Eastern Time to discuss its fourth quarter 2025 financial results and provide an operational update, aiming to enhance investor understanding and confidence in the company's performance.
- Participation Details: Investors can pre-register via a provided link to receive dial-in information, and the call will also be accessible through a live audio webcast on the company's website, ensuring broad participation and transparency.
- Replay Information: An audio replay of the call will be available starting at 11:00 a.m. Eastern Time on February 26, 2026, allowing investors to access the information conveniently through the company website or designated phone numbers.
- Company Background: Teleflex, as a global provider of medical technologies, is committed to improving health and quality of life, with a diverse portfolio covering anesthesia, emergency medicine, interventional cardiology, and more, showcasing its leadership in the healthcare industry.
See More
Teleflex Under Investigation for Securities Fraud Claims
- Executive Departure Impact: On January 8, 2026, Teleflex announced the immediate departure of CEO Liam Kelly, which resulted in a stock price drop of $16.52, or 13.06%, closing at $110.01 per share, indicating strong market reaction to leadership changes.
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Teleflex and certain officers have engaged in securities fraud or other unlawful business practices, advising investors to contact them for information on joining the class action, highlighting potential governance concerns.
- Legal Background: Pomerantz LLP is recognized as a premier firm in corporate, securities, and antitrust class litigation, having fought for victims of securities fraud for over 85 years, suggesting that this case may have broader legal implications.
- Investor Warning: As the investigation unfolds, Teleflex investors face potential financial risks, particularly as concerns over corporate governance and compliance may influence future investment decisions.
See More
Tejara Capital Increases Stake in Teleflex by 69,700 Shares
- Share Acquisition: Tejara Capital Ltd disclosed an acquisition of 69,700 shares of Teleflex in a February 5 SEC filing, with an estimated transaction value of $8.45 million, indicating confidence in the company's future prospects.
- Asset Allocation Shift: This purchase increased Tejara's stake in Teleflex to 2.23%, reflecting a strategic positioning in the medical device sector, despite the stock's nearly 39% decline over the past year.
- Financial Performance: Teleflex's recent earnings report revealed a 19.4% year-over-year increase in GAAP revenue to $913 million, with adjusted EPS rising to $3.67, showcasing operational growth despite impairment challenges.
- Market Positioning: Teleflex focuses on single-use medical devices and boasts a robust global distribution network, offering a relatively stable risk profile compared to Tejara's other high-volatility investments in energy and biotech sectors.
See More
Eos Management Establishes New Position in Teleflex
- New Position: Eos Management disclosed a new stake in Teleflex with 30,831 shares valued at $3.76 million as of December 31, indicating a strategic investment in the medical device sector.
- Holding Proportion: This position represents 1.48% of Eos's 13F reportable assets, reflecting confidence in Teleflex's potential despite a 42.5% decline in stock price over the past year.
- Performance Outlook Adjustment: Teleflex recently narrowed its 2025 revenue growth outlook from 9.0%-10.0% to 9.1%-9.6%, highlighting operational uncertainties that may impact investor confidence.
- Strategic Focus: Teleflex is shrinking to concentrate on high-acuity hospital markets and plans to improve long-term growth and margins through divestitures, which may present future opportunities for investors.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Affirm Holdings Upgrade: Needham analyst Kyle Peterson upgraded Affirm Holdings Inc (NASDAQ:AFRM) from Hold to Buy with a $100 price target, which, given its closing price of $68.71 on Monday, could attract more investor interest.
- CoStar Group Upgrade: BTIG analyst Jake Fuller upgraded CoStar Group Inc (NASDAQ:CSGP) from Neutral to Buy with a price target of $80, based on its closing price of $65.81 on Monday, suggesting increased market confidence following this upgrade.
- Teleflex Upgrade: Needham analyst Mike Matson upgraded Teleflex Inc (NYSE:TFX) from Hold to Buy with a target price of $138, considering its closing price of $104.20 on Monday, indicating potential upward movement in stock price due to this upgrade.
- CoreWeave Upgrade: Deutsche Bank analyst Brad Zelnick upgraded CoreWeave Inc (NASDAQ:CRWV) from Hold to Buy and raised the price target from $100 to $140, based on its closing price of $98.31 on Monday, which may trigger positive investor reactions to this rating change.
See More
